Industry Newsradioligand therapyoncologynovartisbiomanufacturing
Novartis Builds Radioligand Therapy Site in Texas
5.1
Novartis announced on February 25 it will build a 46,000-square-foot radioligand therapy (RLT) manufacturing site in Denton, Texas, with construction starting in 2026 and full operations expected in 2028. The facility, the company’s fifth U.S. RLT site and first in Texas as part of a $23 billion U.S. investment, is expected to create advanced manufacturing and bioengineering jobs and expand cancer-treatment capacity.
Key Points
- 1Announces 46,000 sq ft radioligand therapy manufacturing site in Denton, Texas; construction from 2026.
- 2Signals expansion of US manufacturing footprint as fifth RLT site, part of $23 billion US investment.
- 3Creates advanced manufacturing, bioengineering, quality, and operations jobs, improving capacity to meet growing RLT demand.
Scoring Rationale
Moderate company expansion increases manufacturing capacity, but limited AI/ML relevance and shallow reporting constrain broader impact.
Sources
Public references used for this report.
Practice with real Ad Tech data
90 SQL & Python problems · 15 industry datasets
Used by DS/ML engineers at top companies
Active Search Campaigns by BudgetEasyHigh CPC Clicks & Poor Landing PagesMediumCampaign ROAS by Attribution ModelHard
250 free problems · No credit card
See all Ad Tech problems
